BI 770371

· Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for BI 770371, covering 2025-10-28 to 2026-04-20. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab [Phase 1]

See pricing